Ubs Group Ag Pharming Group N.V. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Pharming Group N.V. stock. As of the latest transaction made, Ubs Group Ag holds 10 shares of PHAR stock, worth $91. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$91

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.35 - $10.6 $73 - $106	10 New	10 $0
Q2 2024 Aug 13, 2024	BUY	$7.27 - $11.3 $5,357 - $8,328	737 Added 1417.31%	789 $6,000
Q1 2024 May 13, 2024	BUY	$10.84 - $13.2 $563 - $686	52 New	52 $0
Q1 2023 May 12, 2023	SELL	$10.24 - $14.96 $3,788 - $5,535	-370 Reduced 29.58%	881 $11,000
Q4 2022 Feb 08, 2023	SELL	$9.17 - $13.5 $2,595 - $3,820	-283 Reduced 18.45%	1,251 $13,000
Q3 2022 Nov 10, 2022	BUY	$6.85 - $12.62 $424 - $782	62 Added 4.21%	1,534 $15,000
Q2 2022 Aug 10, 2022	BUY	$6.61 - $9.64 $1,388 - $2,024	210 Added 16.64%	1,472 $13,000
Q1 2022 May 16, 2022	SELL	$7.75 - $10.05 $511 - $663	-66 Reduced 4.97%	1,262 $11,000
Q4 2021 Feb 14, 2022	BUY	$7.58 - $10.1 $9,202 - $12,261	1,214 Added 1064.91%	1,328 $12,000
Q3 2021 Nov 15, 2021	SELL	$9.26 - $11.6 $11,158 - $13,978	-1,205 Reduced 91.36%	114 $1,000
Q2 2021 Aug 13, 2021	SELL	$10.95 - $13.58 $13,019 - $16,146	-1,189 Reduced 47.41%	1,319 $15,000
Q1 2021 May 12, 2021	BUY	$12.44 - $14.99 $19,804 - $23,864	1,592 Added 173.8%	2,508 $32,000
Q4 2020 Feb 11, 2021	BUY	$14.5 - $16.7 $13,282 - $15,297	916 New	916 $14,000

Others Institutions Holding PHAR

# of Institutions

Shares Held

73.6K

Call Options Held

Put Options Held

View Full List

About Pharming Group N.V.

Ticker PHAR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,241,400
Market Cap $595M
Description
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the tre...

More about PHAR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account